Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Int J Hyperthermia. 2013 Aug;29(5):464-73. doi: 10.3109/02656736.2013.807440. Epub 2013 Jul 17.
Cancer immunotherapy aims to generate long-lived, tumour-specific adaptive immunity to limit dysregulated tumour progression and metastasis. Tumour vasculature has emerged as a critical checkpoint controlling the efficacy of immunotherapy since it is the main access point for cytotoxic T cells to reach tumour cell targets. Therapeutic success has been particularly challenging to achieve because of the local, cytokine-rich inflammatory milieu that drives a pro-tumourigenic programme supporting the growth and survival of malignant cells. Here, we focus on recent evidence that systemic thermal therapy can switch the activities of the inflammatory cytokine, interleukin-6 (IL-6), to a predominantly anti-tumourigenic function that promotes anti-tumour immunity by mobilising T cell trafficking in the recalcitrant tumour microenvironment.
癌症免疫疗法旨在产生持久的、肿瘤特异性的适应性免疫，以限制失调的肿瘤进展和转移。肿瘤血管系统已成为控制免疫疗法疗效的关键检查点，因为它是细胞毒性 T 细胞到达肿瘤细胞靶标的主要进入点。由于局部富含细胞因子的炎症微环境驱动支持恶性细胞生长和存活的促肿瘤发生程序，治疗的成功尤其具有挑战性。在这里，我们关注的是最近的证据表明，全身热疗可以将炎症细胞因子白细胞介素-6 (IL-6) 的活性转变为主要的抗肿瘤功能，通过在顽固的肿瘤微环境中动员 T 细胞迁移来促进抗肿瘤免疫。
